Metabolism of dexrazoxane (ICRF-187) used as a rescue agent in cancer patients treated with high-dose etoposide

@article{Schroeder2003MetabolismOD,
  title={Metabolism of dexrazoxane (ICRF-187) used as a rescue agent in cancer patients treated with high-dose etoposide},
  author={Patricia E. Schroeder and Peter Buhl Jensen and Maxwell Sehested and Kenneth Francis Hofland and Seppo Wang Langer and Brian B. Hasinoff},
  journal={Cancer Chemotherapy and Pharmacology},
  year={2003},
  volume={52},
  pages={167-174}
}
The study was undertaken to determine the metabolism of dexrazoxane (ICRF-187) to its one-ring open hydrolysis products and its two-rings opened metal-chelating product ADR-925 in cancer patients with brain metastases treated with high-dose etoposide. In this phase I/II trial dexrazoxane was used as a rescue agent to reduce the extracerebral toxicity of etoposide. Dexrazoxane and its one-ring open hydrolysis products were determined by HPLC and ADR-925 was determined by a fluorescence flow… CONTINUE READING